[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alopecia-areata\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alopecia-areata":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,49,83,106,140,162,186,205,231,255,284,303,324,351,371,394,423,444,467,490,520,547,568,591,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":46,"locationsCount":4},"100374756","expanded-access-to-upadacitinib-100374756",false,"NCT04159597","Expanded Access to Upadacitinib","Exclusion Criteria:\n\n* There are other suitable treatment options.\n* The participant qualifies for ongoing clinical trials.","ALL","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[20,21,22,23,24,25,26,27,28,29,30,31,32,33],"Crohn Disease","Ulcerative Colitis","Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)","Atopic Dermatitis","Rheumatoid Arthritis","Psoriatic Arthritis","Axial Spondyloarthritis","Non-radiographic Axial","Spondyloarthritis","Giant Cell Arteritis","Systemic Lupus Erythematosus","Alopecia Areata","Non Segmental Vitiligo","Hidradenitis Suppurativa",[35,36,37,38,39,40],"Expanded Access","Pre-approval Access","Compassionate Use","Special Access Program","Named Patient Basis","Special Access Scheme","AVAILABLE","2026-08-18",{"date":44,"type":45},"2026-08-20","ACTUAL",{"name":47,"class":48},"AbbVie","INDUSTRY",{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100640974","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-japanese-adults-with-severe-alopecia-areata-100640974","NCT07617597","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period","THRIVE-AAJP","Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.\n* Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.\n* SALT score of 50 or more at both Screening and Baseline.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.\n* Treatment with biologics within 6 months prior to Screening.\n* Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.\n* History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.\n* Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.","18 Years","65 Years",{"count":60,"type":61},78,"ESTIMATED","INTERVENTIONAL",[64],"PHASE3","This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.",[31],[68,69,70,71,72],"alopecia areata","severe alopecia areata","hair loss","deuruxolitinib","JAK inhibitor","RECRUITING","2026-08-17",{"date":42,"type":45},{"date":77,"type":45},"2026-06-19",{"date":79,"type":61},"2028-09",{"name":81,"class":48},"Sun Pharma Japan Limited",18,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100559295","corevitas-international-adolescent-alopecia-areata-aa-drug-safety-and-effectiveness-registry-100559295","NCT06562270","CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry","Inclusion Criteria:\n\nTo be eligible to participate in this registry, an individual must meet all the following criteria:\n\n1. Has ever been diagnosed with severe AA by a dermatologist or a qualified healthcare provider.\n2. Is 12-17 years of age at the time of enrollment.\n3. Is willing to provide consent\u002Fassent for participation in the registry.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in the registry:\n\n1. Is participating or planning to participate in a blinded clinical trial for any investigational medication.\n2. Is unwilling or unable to provide standing height measurements.","12 Years","17 Years",{"count":92,"type":61},1500,"OBSERVATIONAL","Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines\u002Fregulations in the country where the participating registry site is located.",[31],"2026-08-13",{"date":74,"type":45},{"date":99,"type":45},"2024-03-07",{"date":101,"type":61},"2099-12-31",{"name":103,"class":104},"CorEvitas","NETWORK",1,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":62,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100583255","phase-3-a-study-of-2-doses-of-ritlecitinib-in-people-12-years-of-age-and-older-with-alopecia-areata-100583255","NCT06873945","A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata","A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA","ALLEGRO-100","Inclusion Criteria:\n\nAge:\n\n1. 18 years of age or older at screening. Adolescents (12 to \\\u003C18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB\u002FEC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled. In Part 2 of the study, only adolescents (12 to \\\u003C18 years of age at both Screening and Day 1) who did not participate in Part 1 will be enrolled.\n\n   Disease Characteristics:\n2. Must meet the following alopecia areata criteria at both Screening and Baseline:\n\n   1. Have a clinical diagnosis of alopecia areata with no other etiology of hair loss.\n   2. ≥50% hair loss of the scalp, as measured by SALT, without evidence of terminal hair regrowth within the previous 6 months.\n   3. Current episode of hair loss ≤10 years.\n\nExclusion Criteria:\n\nMedical Conditions:\n\n1. Diseases or conditions other than alopecia areata which affect hair loss, including other types of alopecia, other scalp disease that may impact the alopecia areata assessment, or active systemic diseases that may cause hair loss.\n2. History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy\u002Fhypersensitivity to any component (including excipients) of the study intervention.\n3. Any psychiatric condition including recent or active suicidal ideation or behavior that meets protocol-defined criteria.\n4. General Infection History:\n\n   * Have a history of systemic infection requiring hospitalization or parenteral therapy (antimicrobial, antiviral, antiparasitic, antiprotozoal, or antifungal), or as otherwise judged clinically significant by the investigator, within 3 months prior to Day 1.\n   * Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.\n   * Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.\n5. Specific Viral Infection History:\n\n   * History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.\n   * Infected with hepatitis B or hepatitis C viruses: all participants will undergo screening for hepatitis B and C for eligibility.\n6. Other Medical Conditions:\n\n   * Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating or progressive.\n   * Abnormal findings on the screening chest imaging (eg, chest x-ray) including, but not limited to, presence of active TB or other infections, cardiomyopathy, or malignancy. Chest imaging may be performed up to 12 weeks prior to Screening.\n   * Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n   * Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n   * Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery.\n7. Adolescent participants 12 to \\\u003C18 years of age without one of the following:\n\n   * Documented evidence from a health professional of having received varicella vaccination (2 doses); or\n   * Evidence of prior exposure to varicella zoster virus (VZV) based on serological testing (ie, a positive VZV IgG Ab result) at Screening.\n8. Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n\n   Prior\u002FConcomitant Therapy:\n9. Current or prior use of any prohibited medication(s), vaccine(s), or treatment(s) within the protocol-defined timelines.\n\n   Prior\u002FConcurrent Clinical Study Experience:\n10. Previous administration with an investigational drug or vaccine within 8 weeks (or longer as determined by the local requirement) or 5 half-lives (whichever is longer) before the first dose of study intervention in this study. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. Receipt of study intervention in Study B7981094 or other studies of ritlecitinib.\n\n    Diagnostic Assessments:\n11. Any exclusionary abnormalities in laboratory values at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat.\n12. Screening standard 12-lead ECG that demonstrates clinically relevant abnormalities.\n\n    Other Exclusion Criteria:\n13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",{"count":115,"type":61},1330,[64],"The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body.\n\nRitlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.\n\nThis study is seeking participants who:\n\n* Are 12 years of age or older (Part 1)\n* Are 12 to less than 18 years (Part 2)\n* Have a diagnosis of alopecia areata\n* Have lost 50% or more of the hair on their scalp\n* Do not have any other conditions that causes hair loss\n* Are willing to stop all other treatments that they may be taking for alopecia areata\n\nAbout 550 participants will take part in Part 1 of this study. About 80 participants will take part in Part 2 of this study.\n\nIn Part 1, participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily.\n\nThe 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective.\n\nIn Part 2, all eligible participants will receive ritlecitinib 100 mg taken by mouth once daily. The data from this part of the study will be combined with the data from Part 1 of the study to help to see if the 100 mg dose of ritlecitinib is safe and effective in adolescent patients with alopecia areata.\n\nPeople will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as:\n\n* alopecia areata assessment,\n* physical examinations,\n* hearing tests,\n* blood tests,\n* x-ray,\n* ECG (electrocardiogram),\n* photographs of the scalp and eyes (Part 1 only). Participants will also be asked to complete questionnaires about their alopecia areata.",[31],[120,121,122,123,124,125,126,127,128,70,129,130],"alopecia universalis","alopecia totalis","alopecia","patchy hair loss","diffuse hair loss","ophiasis","hair disease","Ritlecitinib","Litfulo","adolescents","adults","2026-08-11",{"date":96,"type":45},{"date":134,"type":45},"2025-04-01",{"date":136,"type":61},"2028-03-19",{"name":138,"class":48},"Pfizer",147,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":57,"enrollmentInfo":147,"targetDuration":4,"studyType":62,"phases":149,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":105},"100651623","phase-1-a-phase-i-study-of-vc005-tablets-in-adolescent-subjects-with-severe-alopecia-areata-100651623","NCT07762443","A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata","A Phase I Study to Evaluate the Pharmacokinetics, Safety, and Preliminary Efficacy of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata","Inclusion Criteria:\n\n* The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF).\n* Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 40 kg.\n* Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period.\n* Subjects with a current diagnosis of acute diffuse alopecia areata (AA).\n* Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc.\n* Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.",{"count":148,"type":61},24,[150],"PHASE1","This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).",[31],"NOT_YET_RECRUITING","2026-08-09",{"date":96,"type":45},{"date":157,"type":61},"2026-09-30",{"date":159,"type":61},"2027-12-30",{"name":161,"class":48},"Jiangsu vcare pharmaceutical technology co., LTD",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":62,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100633924","phase-2-a-study-of-ly4005130-in-adult-participants-with-severe-alopecia-areata-hair-loss-100633924","NCT07533006","A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)","A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata","Inclusion Criteria:\n\n* Have severe Alopecia Areata (AA) that meets all of the following criteria:\n\n  * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score\n  * The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years\n  * No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months\n  * Agree not to use any AA treatments during the study\n\nExclusion Criteria:\n\n* Primarily \"diffuse\" type of AA (characterized by diffuse hair shedding)\n* Are currently experiencing other forms of alopecia\n* Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and\u002For frequent use of systemic immunosuppressants that may interfere with participation in the study\n* Have received oral JAK Inhibitors in the past\n* Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness","50 Years",{"count":171,"type":61},60,[173],"PHASE2","The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study drug will be administered intravenously (IV) (into a vein in the arm).\n\nThe study will last approximately 48 weeks, including screening.",[31],"2026-08-05",{"date":178,"type":45},"2026-08-06",{"date":180,"type":45},"2026-04-14",{"date":182,"type":61},"2027-10",{"name":184,"class":48},"Eli Lilly and Company",30,{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":193,"targetDuration":4,"studyType":62,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":105},"100650647","phase-2-phase-ii-clinical-study-of-vc005-tablets-in-subjects-with-severe-alopecia-areata-100650647","NCT07749716","Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata","Inclusion Criteria:\n\n* Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written informed consent by signing the informed consent form (ICF).\n* Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender.\n* Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period.\n* Subjects with a current diagnosis of acute diffuse alopecia areata (AA).\n* Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc.\n* Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.",{"count":194,"type":61},120,[173],"This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).",[31],"2026-08-03",{"date":178,"type":45},{"date":201,"type":61},"2026-08-15",{"date":203,"type":61},"2028-12-30",{"name":161,"class":48},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":93,"phases":4,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100650478","an-observational-study-of-patients-with-dermatologic-disease-100650478","NCT07748169","An Observational Study of Patients With Dermatologic Disease","TARGET-DERM+","Inclusion Criteria:\n\n* Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.\n* Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.\n\nExclusion Criteria:\n\n* Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.",{"count":213,"type":61},2000000,"15 Years","TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and\u002For data from providers who treat them.",[217,23,31,218],"Vitiligo","Hidradenitis Suppurativa (HS)",[220,221],"Dermatologic Disease","DERM+","2026-07-31",{"date":176,"type":45},{"date":225,"type":61},"2026-08-01",{"date":227,"type":61},"2041-08-03",{"name":229,"class":48},"Target PharmaSolutions, Inc.",3,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":62,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},"100517030","phase-3-a-study-to-evaluate-the-safety-and-effectiveness-of-upadacitinib-tablets-in-adult-and-adolescent-participants-with-severe-alopecia-areata-100517030","NCT06012240","A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata","A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata","Up-AA","Inclusion Criteria:\n\n* Adult individuals must be \\\u003C 64 years old at Baseline Visit. Where permitted outside United States (US)\u002FEuropean Union (EU), adolescent individuals who are at least 12 years old at Screening may participate in Study 1 and Study 2. Adolescent individuals in the US who are at least 12 years old at Screening may participate in Study 4.\n* Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score \\>= 50 scalp hair loss at Screening and Baseline.\n* Severe AA with no spontaneous scalp hair regrowth over the past 6 months.\n* Current episode of AA of less than 8 years.\n\nExclusion Criteria:\n\n* Current diagnosis of primarily diffuse type of AA.\n* Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium.\n* Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.","63 Years",{"count":92,"type":61},[64],"Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA.\n\nUpadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide.\n\nParticipants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[31],[31,245,246,247],"Upadacitinib","Rinvoq","ABT-494",{"date":198,"type":45},{"date":250,"type":45},"2023-10-11",{"date":252,"type":61},"2030-04",{"name":47,"class":48},283,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":262,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":263,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":265,"conditions":266,"keywords":270,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":105},"100649297","serum-ferroptosis-biomarkers-gpx4-mda-in-alopecia-areata-100649297","NCT07733063","Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata","Evaluation of Serum Ferroptosis Biomarkers (GPX4 and MDA) and Their Relationship With Disease Stage, Clinical Severity, and Trichoscopic Findings in Patients With Alopecia Areata","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Formally diagnosed with Alopecia Areata based on clinical and trichoscopic examination.\n* Healthy volunteers with no personal or family history of alopecia or any systemic inflammatory\u002Fautoimmune conditions (for the healthy control group).\n* Patients who have provided written informed consent before any study-related procedures.\n\nExclusion Criteria:\n\n* Use of topical corticosteroids, intralesional steroid injections, or topical calcineurin inhibitors within the last 1 month.\n* Use of systemic immunosuppressive therapies, systemic corticosteroids, or JAK inhibitors within the last 3 months.\n* Presence of any other co-existing active autoimmune or inflammatory skin diseases (e.g., Psoriasis, Vitiligo, or active autoimmune thyroiditis with elevated TSH levels).\n* History of malignancy, active severe infection, chronic hepatic failure, or chronic renal failure.\n* Pregnancy or lactation.\n* History of heavy smoking or uncontrolled\u002Fregular use of antioxidant or vitamin supplements (e.g., Vitamin E, Vitamin C, CoQ10, NMN, resveratrol).",true,{"count":264,"type":61},156,"This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA). Serum concentrations of two key ferroptosis biomarkers-Glutathione Peroxidase 4 (GPX4), a primary antioxidant enzyme protecting against lipid peroxidation, and Malondialdehyde (MDA), a major end-product of lipid membrane damage-will be quantitatively measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits.\n\nA total of 156 participants will be enrolled, consisting of 104 patients diagnosed with Alopecia Areata (subdivided into acute and chronic cohorts) and 52 age- and sex-matched healthy controls. Serum biomarker levels will be statistically compared among the groups to determine their diagnostic value. Furthermore, these biomarker levels will be correlated with clinical disease extension evaluated via the Severity of Alopecia Tool (SALT) score and objective trichoscopic activity findings (such as black dots, yellow dots, and exclamation mark hairs). The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.",[267,31,268,269],"Alopecia Areata(AA)","Alopecia Areata (& Ophiasis)","Alopecia",[271,68,272,273],"ferroptosis","GPX4","MDA","2026-07-29",{"date":276,"type":45},"2026-07-30",{"date":278,"type":45},"2026-06-01",{"date":280,"type":61},"2027-01-01",{"name":282,"class":283},"Istanbul Training and Research Hospital","OTHER_GOV",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":62,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},"100649470","phase-3-a-study-in-young-people-and-adults-to-learn-about-the-medicine-ritlecitinib-for-treatment-of-patchy-hair-loss-known-by-the-medical-term-as-moderate-alopecia-areata-100649470","NCT07733765","A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata","A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA","Key Inclusion Criteria\n\n* 18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to \\\u003C18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB\u002FEC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled\n* Have a clinical diagnosis of AA with no other etiology of hair loss.\n* Have \\>20% to \\\u003C50% hair loss of the scalp, as measured by SALT.\n* Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches).\n\nKey Exclusion Criteria\n\n1\\. Diseases or conditions affecting hair loss, including:\n\n* Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded.\n* Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).\n* Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).",{"count":292,"type":61},336,[64],"The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).\n\nThis study is seeking participants who are\n\n* 12 years or older (if permitted by the local IRB\u002FEC and local regulatory health authority)\n* have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less\n* do not have any other diseases or conditions affecting hair loss.\n\nParticipants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks.\n\nAbout 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone.\n\nWe will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.",[31],"2026-07-24",{"date":274,"type":45},{"date":222,"type":61},{"date":300,"type":61},"2028-04-27",{"name":138,"class":48},4,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100556899","characterization-and-clinical-outcomes-of-aa-patients-treated-with-ritlecitinib-100556899","NCT06531109","Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib","PRESTO - CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AREATA (AA) PATIENTS TREATED WITH RITLECITINIB IN A REAL-WORLD (RW) COHORT: A MULTINATIONAL, PROSPECTIVE OBSERVATIONAL STUDY.","PRESTO","Inclusion Criteria:\n\n1. Male and female patients aged \\>12 years at baseline.\n2. Patients with diagnosis of alopecia areata confirmed by a certified dermatologist, who are prescribed ritlecitinib as per the product label independently of the decision to enroll a patient in this study.\n3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Following receipt of oral and written information about the trial, the adolescent (depending on local institutional review board\u002Findependent ethics committee requirements) must provide assent, and one or both (according to local regulations) parents or guardians of the child must provide signed informed consent before any study-related activity is carried out.\n4. Patients, who in the opinion of the investigator, are willing and able to comply with regular clinic visits as per standard practice at the site and agree to complete PRO questionnaires and other patient completed questions.\n\nExclusion Criteria:\n\n1. Diagnosed with other types of alopecia or other diseases that can cause hair loss (including, but not limited to known androgenetic alopecia, traction and scarring alopecia, telogen effluvium).\n2. Diagnosed with other scalp diseases that may impact AA assessment (e.g., scalp psoriasis, dermatitis, etc.) or other active systemic diseases that may cause hair loss (e.g., lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc.). that could interfere with assessment of hair loss\u002Fregrowth.\n3. Patients previously treated with ritlecitinib or other JAK inhibitors.\n4. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.",{"count":312,"type":61},450,"Alopecia areata (AA) is a chronic relapsing autoimmune disease characterized by nonscarring hair loss affecting children, adolescents, and adults across all ages, races, and genders. AA primarily affects the scalp; however, it also can affect nails, eyelashes, eyebrows, and other hair follicles on the patient's body. The 3 main types of AA are:\n\n* Patchy alopecia (PA), as seen in 90% of clinical diagnoses\n* Alopecia totalis (AT), that affects all scalp hair\n* Alopecia universalis (AU), involving all scalp, face, and body hair Dermatologist preferences for utility and order of skin-directed therapies to treat AA vary widely, with treatment choices based on various factors such as patients' age, disease duration and severity (Meah et al., 2020).\n\nRitlecitinib is a bioavailable small molecule that irreversibly binds to Janus kinase-3 (JAK3) and Tyrosine kinase Expressed in the hepatocellular Carcinoma kinase family (TEC). Ritlecitinib 50 mg once daily was approved by the FDA 23 June 2023 and EMA 20 July 2023 for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In Japan, ritlecitinib was approved on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Additional countries have since approved ritlecitinib. Those approvals are based on the results of the ritlecitinib pivotal phase 2b\u002F3 study (ALLEGRO 2b\u002F3) which examined efficacy and safety of ritlecitinib in AA patients globally.\n\nDespite positive results from the ALLEGRO program, there is still lack of evidence on ritlecitinib patients' characteristics and clinical outcomes in routine clinical practice. The investigators will evaluate patient and disease characteristics, treatment patterns, and clinical and patient-reported outcomes among patients with AA who are receiving ritlecitinib.\n\nThe aim of this study is to measure effectiveness of ritlecitinib in a real-world setting. Ritlecitinib will be prescribed to patients according to the approved product label. Treatment will be guided by clinical judgement of the treating physician ie, study investigators, according to standard of care, independently of this study.",[31],"2026-07-21",{"date":317,"type":45},"2026-07-23",{"date":319,"type":45},"2024-08-07",{"date":321,"type":61},"2028-04-15",{"name":138,"class":48},81,{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":331,"targetDuration":4,"studyType":62,"phases":332,"briefSummary":334,"conditions":335,"keywords":339,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":105},"100647211","the-role-of-gut-and-skin-microbiota-in-alopecia-areata-100647211","NCT07705217","The Role of Gut and Skin Microbiota in Alopecia Areata","RGSM-AA-ICS","Inclusion Criteria:\n\n1. Adults aged 18-65 diagnosed with Alopecia Areata (patchy or extensive) up to 10 years\n2. Willingness to adhere to study protocols, including FMT administration via capsules or colonoscopy.\n3. Ability to sign informed consent.\n4. SALT score≥ 20\n\nExclusion Criteria:\n\n1. History of gastrointestinal disorders (e.g., IBD, celiac disease).\n2. Recent use of antibiotics, probiotics, or prebiotics (within 2 months).\n3. Pregnant or breastfeeding women of childbearing potential who are unwilling or unable to use an acceptable method of birth control.\n4. Individuals with immunocompromised or immunosuppressed states (e.g., HIV, cancer).\n5. Prior FMT treatment for any condition.\n6. Therapy with new antidepressants or had a change in antidepressant dose within previous 3 months\n7. Serious medical comorbidities(including neurological or phychiatric comorbidities)\n8. Elevated C-reactive protein concentration, abnormal baseline laboratory tests\n9. Severe(anaphylactic) food allergy\n10. Concomitant treatments for AA: topical KS 1 week prior to randomization, topical JAK inhibitor, diphenylcyclopropenone, or other topical immunotherapies within 4 weeks prior to randomization;systemic corticosterids, immunosuppressant, intra-lesional or intra-articular corticosteroid injections, or oral JAK inhibitor within 8 weeks prior to randomization;monoclonal antibody \\\u003C5 half-lives prior to randomization; probenecid at the time of randomization. Bimatoprost ophtalmic solution was allowed if on stable dose for 8 weeks.",{"count":185,"type":61},[333],"NA","The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) works to treat alopecia areata in adults. It will also learn about the safety of FMT. The main questions it aims to answer are:\n\n* Can FMT cause hair regrowth?\n* Can FMT modulate immune response? Researchers will compare FMT to a placebo (a look-alike substance that contains no drug) to see if FMT works to treat alopecia areata.\n\nParticipants will:\n\n* Take FMT or a placebo for three consecutive days\n* Follow-up evaluations will be performed at weeks 12, 24, and 48, with repeat clinical scoring, photodocumentation, microbiome analyses, laboratory testing, and quality-of-life assessment.",[31,336,337,338],"Fecal Microbiota Transplantation (FMT)","T Cell Subsets","Microbiome",[68,340,341],"Fecal microbiota transplantation","FMT","2026-07-10",{"date":344,"type":45},"2026-07-15",{"date":346,"type":61},"2026-10",{"date":182,"type":61},{"name":349,"class":350},"Polyclinic GrandMed","OTHER",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":62,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100646042","new-topical-treatment-in-patchy-alopecia-areata-100646042","NCT07696585","New Topical Treatment in Patchy Alopecia Areata","Efficacy and Safety of Topical Therapy of Metformin 30%; Simvastatin 2%; and Betamethasone Valerate 0.1% in Treatment of Patients With Patchy Alopecia Areata","Inclusion Criteria:\n\n\\- Patients of both sexes aged ≥ 6 years (children and adults), having clinical and trichscopic finding of alopecia areata (involving \\\u003C 50% of the total scalp) and did not receive any topical or systemic treatment in the last 3 months for alopecia areata.\n\nExclusion Criteria:\n\n* Alopecia totalis and alopecia universalis.\n* Cicatricial alopecia.\n* Other causes of hair loss such as; endocrine or immunological disease.\n* Skin disease in the affected area.\n* Hypersensitivity to any of the treatment products used.","6 Years",{"count":171,"type":61},[333],"Alopecia areata (AA) is a chronic immune disease characterized by non-scarring hair loss of the scalp or other hair-bearing areas Patients with AA frequently report high levels of dissatisfaction with commonly used treatment options due to ineffectiveness and adverse effects. Therefore, a substantial unmet need exists for safe and effective treatments for patients with AA. Metformin is a derivative of biguanide that is the most widely used as an oral antihyperglycemic agent for the control of diabetes mellitus. The main mechanism of action for metformin involves enhancing insulin sensitivity, reducing gluconeogenesis, and promoting the absorption of glucose in muscles.\n\nIn addition to its hypoglycemic effect, metformin can serve as an anti-inflammatory agent.Statins are hydroxy-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly used for their lipid-lowering properties to lower cholesterol levels and treat cardiovascular disease, but they also possess powerful anti-inflammatory and immunomodulatory effects.\n\nSimvastatin belongs to the statin family. Lately, Simvastatin is utilized in treatment of several dermatological diseases. It showed efficacy in treatment of psoriasis , vitiligo, xanthomas, atopic dermatitis and acne vulgaris.\n\nThis study is considered as the first study to assess and compare the efficacy and safety of of topical therapy of metformin 30 %; simvastatin 2 %; and betamethasone valerate 0.1 % in treatment of patients with patchy alopecia areata.",[31],"2026-07-06",{"date":342,"type":45},{"date":366,"type":61},"2026-06-28",{"date":368,"type":61},"2027-12-28",{"name":370,"class":350},"Sohag University",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":62,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":105},"100573540","phase-2-evaluation-of-microbiota-transplant-therapy-in-patients-with-alopecia-areata-100573540","NCT06747611","Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata","Inclusion Criteria:\n\n* Patients 18 to 75 years of age with moderate to severe alopecia areata (SALT score \\>30%).\n* Patients with a diagnosis of patch type alopecia areata, totalis, or universalis..\n* Duration of hair loss \\>=3 months..\n* No evidence of active, ongoing regrowth present at baseline.\n* Females of childbearing potential must have a negative urine or serum pregnancy test at screening and immediately prior to MTT.\n* Females of childbearing potential must agree to use an effective form of contraception from 14 days prior to study antibiotics through at least 30 days after MTT. Acceptable forms of contraception include oral or intramuscular contraceptives, intrauterine devices, surgical sterilization.\n* Participants are not enrolled in another clinical study.\n* If undergoing treatment with a JAK inhibitor, participant is willing to discontinue treatment for 1 month prior to enrollment and throughout the duration of the study.\n\nExclusion Criteria:\n\n* Active gastrointestinal infection at time of enrollment.\n* Having been administered antibiotics in the last 48 hours.\n* Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to treatment..\n* Requires continued antibiotic use\n* Allergy to study antibiotics (vancomycin, neomycin).\n* Known or suspected severe gastrointestinal dysmotility disorder, e.g., gastroparesis, pseudo-obstruction, scleroderma with gastrointestinal involvement\n* Ileus or small bowel obstruction.\n* Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy.\n* History of total colectomy.\n* Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy.\n* Unable or unwilling to comply with protocol requirements.\n* Expected life expectancy \\< 6 months.\n* Previous MTT or microbiome-based products at any time excluding this study.\n* History of severe anaphylactic or anaphylactoid food allergy.\n* Solid organ transplant recipients 90 days post-transplant or on active treatment for rejection.\n* A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.\n* History of or existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis and patients with evidence of infection or skin cancer in the treated areas.\n* Patients in whom the diagnosis of alopecia areata is questionable.\n* Patients in whom regrowth is present\u002Fevident at baseline in the areas to be treated.\n* Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma of the skin) which in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.\n* Patients unwilling or unable to discontinue treatments known to affect hair regrowth in alopecia areata.\n* Patients who have been treated with intralesional steroids, systemic steroids, anthralin, squaric acid, DPCP (diphenylcycloprophenone), protopic, minoxidil, JAK inhibitors or other medication which in the opinion of the investigator may affect hair regrowth, within one month of the baseline visit..\n* Patients determined by the investigator to have extreme diets..\n* Pregnant and breastfeeding females..","75 Years",{"count":379,"type":61},40,[173],"Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. AA affects about 5.3 million people in the United States alone, including males and females across all ethnic groups, with a lifetime risk of 2.1%. Autoimmunity develops against the hair follicle, resulting in non-scarring hair loss that may begin as patches that can coalesce and progress to cover the entire scalp (alopecia totalis) or eventually the entire body (alopecia universalis). In AA, there is no permanent destruction of the hair follicle, and regrowth remains possible. Treatment options for AA include intralesional steroids, topical anthralin, allergic contact dermatitis with diphencyprone (DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE), and recently janus kinase ( JAK) inhibitors. Despite the recent approval of JAKs for the treatment of extensive alopecia areata, some patients are treatment resistant, suffer relapses, or cannot take an oral immunosuppressive medication.\n\nThis study will attempt to elucidate the pre-treatment and post treatment skin and gut microbiome composition to determine whether specific bacterial species may correlate with disease or treatment response. To determine the effects of MTT on immune cell composition and activation systemically and locally in the skin, we will analyze major immune cell populations in peripheral blood samples and collect skin biopsies for histopathology and next generation sequencing analyses. Further, to determine if changes in immune cell populations affect the inflammatory response, we will profile inflammatory cytokines. To identify if changes in the gut microbiota influence the metabolic signature in AA, we will also perform untargeted metabolomics in stool gut microbiome samples and in plasma. Altogether, this comprehensive approach aims to identify the pathogenic immunological mechanisms associated with microbiome composition correlated to pre-treatment disease, post-treatment response, and any non-responders to treatment.",[31,383,384],"Alopecia Totalis","Alopecia Universalis","2026-06-25",{"date":387,"type":45},"2026-06-26",{"date":389,"type":45},"2025-08-21",{"date":391,"type":61},"2028-03-15",{"name":393,"class":350},"University of Minnesota",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":262,"sex":16,"minAge":89,"maxAge":377,"enrollmentInfo":401,"targetDuration":4,"studyType":62,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":105},"100469899","phase-2-evaluate-the-efficacy-and-safety-of-ruxolitinib-on-hair-regrowth-in-patients-with-autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy-apeced-associated-alopecia-areata-100469899","NCT05398809","Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","* INCLUSION CRITERIA:\n\nFor participants with APECED-associated AA:\n\n1. Participant must be able to understand and provide informed consent.\n2. Aged \\>=12 to \\\u003C=75 years.\n3. Patients with APECED (genetic or clinical diagnosis) and severe AA (defined as having \\>=50% total scalp loss at screening per the SALT score).\n4. Duration of hair loss greater than 6 months.\n5. No present evidence of hair regrowth.\n6. Is na(SqrRoot) ve or unresponsive to other treatments for AA.\n7. No treatment for alopecia in the past 2 months prior to study enrollment.\n8. Willingness to use valacyclovir prophylaxis for the prevention of herpes viral reactivation.\n9. Vaccinations should be up to date in agreement with current CDC immunization guidelines prior to start of ruxolitinib.\n10. Proficient in written English.\n11. Participants who can get pregnant or impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at screening until 12 weeks after the last dose. Highly effective contraceptive measures include:\n\n    1. Stable use of combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) starting 1 month prior to screening.\n    2. Intrauterine device; intrauterine hormone-releasing system.\n    3. Two barrier methods (eg, condom with spermicide, diaphragm with spermicide, or cervical cap and spermicide). Internal and external condoms may not be used together.\n    4. Bilateral tubal ligation.\n\nPeriodic abstinence (calendar, symptothermal, and post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception.\n\nFor family members or household contacts:\n\n1. Aged \\>=18 years.\n2. Lives with the participant.\n3. Proficient in written English.\n\nEXCLUSION CRITERIA:\n\nFor participants with APECED-associated AA:\n\n1. Known history of hypersensitivity to ruxolitinib or other JAK inhibitors.\n2. History of or active skin disease on the scalp other than AA, such as psoriasis or seborrheic dermatitis.\n3. Diagnosis of AA is in question or the pattern of hair loss is such that quantification of hair loss and assessment of regrowth is difficult, eg, patients with androgenic alopecia.\n4. Treated within the last 2 months with intralesional steroids, systemic steroids, anthralin, squaric acid, diphenylcyclopropenone, tacrolimus, minoxidil, or other medication that, in the opinion of the investigator, may affect hair regrowth.\n5. Current or recent use of any investigational drug (within 3 months or 5 half-lives, whichever is longer, prior to screening).\n6. Scheduled to participate in another clinical study involving an investigational drug during the course of this study.\n7. Use of systemic immunosuppressive or immune-modulating agents within 3 months prior to screening, except systemic steroids 10 mg of prednisone equivalent per day.\n8. Current use of systemic steroids with daily dose \\>10 mg of prednisone equivalent for any reason or steroid burst for \\>3 days within 1 month of screening.\n9. History of alcohol or drug abuse within 6 months prior to screening.\n10. Presence of one or more of the following clinically significant laboratory abnormalities:\n\n    1. Serum ALT\\>=3 times upper limit of normal (ULN).\n    2. Serum total bilirubin \\>=2 times ULN.\n    3. ANC\\\u003C=1000 cells\u002Fmicroliter.\n    4. Hemoglobin \\\u003C=9.0 g\u002FdL.\n    5. Platelet count \\\u003C=100,000\u002Fmicroliter.\n    6. Serum creatinine \\>=2 times ULN.\n11. Planned or anticipated major surgical procedure during the study.\n12. Plans to receive any live vaccines within 1 month of the anticipated first dose of ruxolitinib.\n13. Known or suspected immunodeficiency disorder besides APECED.\n14. History of untreated invasive opportunistic infections (eg, tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, aspergillosis) despite infection resolution or otherwise recurrent infections of\n\n    abnormal frequency or prolonged infections suggesting an immune-compromised status as judged by the investigator.\n15. Untreated latent tuberculosis infection.\n16. Infection with HIV.\n17. Untreated infection with hepatitis B or C.\n18. History of serious bacterial infection within the last 3 months prior to screening, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis).\n19. History of unprovoked DVT, PE, arterial thrombosis, or other thrombotic events.\n20. History of stroke, heart attack, or heart failure.\n21. History of herpes zoster or cytomegalovirus infection that resolved within 2 months prior to screening.\n22. History of basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix, unless the participant is in remission and curative therapy was completed at least 12 months prior to screening.\n23. History of other malignancies, unless the participant is in remission and curative therapy was completed at least 5 years prior to screening.\n24. Planned or anticipated use of any prohibited medications and procedures during the study.\n25. Current pregnancy or breastfeeding.\n26. Past or current medical problems or findings from physical examination, EKG, or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant s ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n\nThere are no exclusion criteria for family members or household contacts.",{"count":402,"type":61},70,[173],"Background:\n\nAutoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA.\n\nObjective:\n\nTo see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body.\n\nEligibility:\n\nPeople aged 12 to 65 years with APECED and severe AA.\n\nDesign:\n\nParticipants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital.\n\nThe first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life.\n\nParticipants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen.\n\nSome tests may be repeated in subsequent in-person visits.\n\nIn telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.",[406,31],"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)",[408,409,410,411,412],"Aps-1","Aire","Jak","Autiommunity","Hair Loss","2026-06-18",{"date":415,"type":45},"2026-06-22",{"date":417,"type":45},"2023-01-18",{"date":419,"type":61},"2027-12-01",{"name":421,"class":422},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":62,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":230},"100481652","phase-2-regeneron-aa-multicenter-dupilumab-100481652","NCT05551793","Regeneron AA Multicenter (Dupilumab)","Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and\u002For High IgE","INCLUSION CRITERIA:\n\n* Male or female subjects who are at least 18 years old at the time of informed consent.\n* Subject is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.\n* Subject is able to adhere to the study visit schedule and other protocol requirements.\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:\n\n  * Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy, OR;\n  * Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural \\[animal\\] membrane \\[for example, polyurethane\\]); PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.\n* If subject is a female of non-childbearing potential, she must have documented history of infertility, be in a menopausal state for one year, or had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.\n* Subject has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score; OR subject has ≥ 95% loss of scalp hair for enrollment as AA totalis (AT) or universalis (AU) subtypes.\n* Subject has a screening IgE \\> 200 and\u002For personal and\u002For familial history of atopy.\n* Subjects must meet the following laboratory criteria:\n\n  * White blood cell count ≥ 3000\u002Fmm3 (≥ 3.0 x 109\u002FL) and \\\u003C 14,000\u002Fmm3 (≤ 14 x 109\u002FL).\n  * Platelet count ≥ 100,000\u002FμL (≥ 100 x 109\u002FL).\n  * Serum creatinine ≤ 1.5 mg\u002FdL (≤ 132.6 μmol\u002FL).\n  * AST (SGOT) and ALT (SGPT) ≤ 2 x upper limit of normal (ULN). If the initial test shows ALT or AST \\> 2 times the ULN, one repeat test is allowed during the Screening Phase.\n  * Total bilirubin ≤ 2 mg\u002FdL (34 μmol\u002FL). If the initial test shows total bilirubin \\> 2 mg\u002FdL (34 μmol\u002FL), one repeat test is allowed during the Screening Phase.\n  * Hemoglobin ≥ 10 g\u002FdL (≥ 6.2 mmol\u002FL).\n* Subject is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nEXCLUSION CRITERIA:\n\nThe presence of any of the following will exclude a subject from enrollment:\n\n* Subject is pregnant or breastfeeding.\n* Subject's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V).\n* Subject has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss.\n* Severe, uncontrolled asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations.\n* Subject has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics\n* Subject with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator.\n* Subject has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n* Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology or active or untreated latent tuberculosis at the time of screening for subjects determined by the investigators to be at high-risk for this disease.\n* Subject has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Subject has received a live attenuated vaccine ≤ 30 days prior to study randomization.\n* Subject has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints.\n* Subject has any other medical or psychological condition that, in the opinion of the investigator, may present additional unreasonable risks as a result of their participation in the study and\u002For interfere with clinic visits and necessary study assessments.\n* History of adverse systemic or allergic reactions to any component of the study drug.\n* Severe, untreated asthma or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic mediations.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, or ultraviolet (UV) phototherapy with\u002Fwithout Psoralen Ultraviolet A (PUVA) therapy within 4 weeks prior to randomization.\n* Use of an oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, or investigational oral JAK Inhibitors) within 12 weeks prior to the Baseline visit.\n* Subject has been previously treated with dupiliumab.\n* Subject has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus within 1 week before the Baseline visit.\n* Subject currently uses or plans to use anti-retroviral therapy at any time during the study.",{"count":431,"type":61},76,[173],"This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and\u002For have personal and\u002For familial history of atopy.\n\nSubjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).",[31],"2026-06-15",{"date":437,"type":45},"2026-06-17",{"date":439,"type":45},"2023-04-10",{"date":441,"type":61},"2028-10-31",{"name":443,"class":350},"Emma Guttman",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":451,"targetDuration":4,"studyType":62,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":105},"100616896","phase-2-a-study-of-lad603-in-adults-with-alopecia-areata-100616896","NCT07311564","A Study of LAD603 in Adults With Alopecia Areata","A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata","Inclusion Criteria:\n\n* Participant is a male or female between 18 and 65 years old at the time of signing the informed consent.\n* Severe to very severe AA criteria:\n\n  1. Greater than or equal to (\\>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits.\n  2. Current episode of hair loss lasting at least 6 months and not exceeding 7 years.\n* Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,\n\nExclusion Criteria:\n\nAA, Skin Specific, and Other Inflammatory Diseases\n\n* Participants have other types of alopecia (including but not limited to traction, scarring alopecia).\n* Participants with \"diffuse\" type AA.\n* Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.\n\nOther Medical Conditions\n\n* Participant has previous severe adverse reaction to subcutaneously administered medication.\n* Participant has any of the following liver safety laboratory results at Screening\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to (\\>=) 2.5 × upper limit of normal (ULN)\n  2. Total bilirubin (TBL) \\>=1.5 × ULN (TBL \\>=3 × ULN in participants with Gilbert's syndrome)\n  3. Alkaline phosphatase (ALP) \\>=1.5 × ULN\n\n     Prior\u002FConcomitant Therapy\n* Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.",{"count":452,"type":61},136,[173],"The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.",[31],[412,457,269],"Hypotrichosis","2026-05-19",{"date":460,"type":45},"2026-05-20",{"date":462,"type":45},"2025-12-17",{"date":464,"type":61},"2027-11-21",{"name":466,"class":48},"Almirall, S.A.",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":16,"minAge":474,"maxAge":58,"enrollmentInfo":475,"targetDuration":4,"studyType":62,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":489},"100524139","phase-2-safety-and-efficacy-of-oral-nxc-736-in-adult-participants-with-moderate-and-severe-alopecia-areata-100524139","NCT06104839","Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata","Inclusion Criteria:\n\n* Men or women between ≥19 and ≤65 years of age at the time of informed consent\n* Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \\\u003C 95% at Screening and Day 1\u002FBaseline\n* Current episode of hair loss for ≥6 months but \\\u003C8 years\n* Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator\n* Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study\n\nExclusion Criteria:\n\n* Participants with the following medical history confirmed during screening:\n\n  * ohter Types of alopecia other than alopecia areata (such as cicatricial\u002Fscarring alopecia \\[including central centrifugal cicatricial alopecia\\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)\n* Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment\n* Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors","19 Years",{"count":476,"type":61},73,[173],"The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).",[31],"2026-04-09",{"date":482,"type":45},"2026-04-13",{"date":484,"type":45},"2024-09-01",{"date":486,"type":61},"2027-01-31",{"name":488,"class":48},"NEXTGEN Bioscience",2,{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":169,"enrollmentInfo":498,"targetDuration":4,"studyType":62,"phases":500,"briefSummary":502,"conditions":503,"keywords":504,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":4},"100628307","phase-4-topical-methotrexate-vs-minoxidil-for-localized-alopecia-areata-100628307","NCT07459933","Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","Comparative Study Between Topical Methotrexate 1% Gel and Minoxidil 5% Spray in the Treatment of Localized Alopecia Areata: A Randomized Controlled Trial","MTX-MNX-AA","Inclusion Criteria:\n\nPatients aged 18 to 50 years.\n\nPatients of either gender.\n\n* Patients diagnosed with localized alopecia areata, defined as one or more smooth, well-circumscribed patches of non-scarring hair loss on the scalp with less than 25% scalp involvement, assessed using the Severity of Alopecia Tool (SALT) score.\n* Patients not previously treated with topical methotrexate or minoxidil for alopecia areata.\n* Patients willing to provide written informed consent and comply with follow-up visits.\n\nExclusion Criteria:\n\n* Patients with other types of alopecia, including androgenetic alopecia, telogen effluvium, or scarring alopecia.\n* Patients with systemic diseases that may influence hair growth or treatment response, such as uncontrolled thyroid disease, uncontrolled diabetes mellitus, or autoimmune connective tissue disorders.\n* Pregnant or lactating women.\n* Patients who have used topical or systemic treatment for alopecia areata within the past 3 months.\n* Patients with known hypersensitivity or allergy to methotrexate or minoxidil.",{"count":499,"type":61},268,[501],"PHASE4","Alopecia areata is an autoimmune disorder characterized by well-defined, non-scarring patches of hair loss on the scalp and other hair-bearing areas. Although several treatment options are available, there is no universally accepted standard therapy, and treatment responses vary widely among patients.\n\nMinoxidil is commonly used for hair regrowth due to its ability to stimulate hair follicles and prolong the anagen phase of the hair cycle. Methotrexate, an immunosuppressive agent traditionally used in inflammatory and autoimmune diseases, has also been explored as a potential treatment for alopecia areata because of its ability to suppress immune-mediated follicular damage.\n\nThis randomized controlled trial aims to compare the efficacy and safety of topical methotrexate 1% gel versus minoxidil 5% spray in patients with localized alopecia areata. Eligible participants will be randomly assigned to receive either topical methotrexate gel or minoxidil spray and will be followed for 24 weeks. Treatment response will be assessed using the Severity of Alopecia Tool (SALT) score. The findings of this study may help identify an effective therapeutic option for patients with localized alopecia areata and contribute to improving clinical management strategies for this condition.",[31],[505,506,507,508,509,510],"Localized Alopecia Areata","Topical Methotrexate","Minoxidil 5%","Hair Regrowth","Autoimmune Hair Loss","SALT Score","2026-03-04",{"date":513,"type":45},"2026-03-10",{"date":515,"type":61},"2026-03-15",{"date":517,"type":61},"2026-09-15",{"name":519,"class":283},"Jinnah Postgraduate Medical Centre",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":169,"enrollmentInfo":528,"targetDuration":4,"studyType":62,"phases":529,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":4},"100627792","phase-4-comparison-of-topical-calcipotriol-and-intralesional-steroids-in-alopecia-areata-100627792","NCT07453238","Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","Comparison of Topical Calcipotriol Versus Intralesional Corticosteroids in the Treatment of Alopecia Areata: A Randomized Controlled Trial","CALISTA-AA","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Clinically diagnosed patchy alopecia areata\n* Scalp involvement of less than 50% (SALT score \\\u003C50%)\n* No topical or systemic treatment for alopecia areata within the previous 3 months\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diffuse alopecia areata or scarring alopecia\n* Presence of other autoimmune diseases or significant systemic illness\n* Known hypersensitivity to calcipotriol or corticosteroids\n* Pregnant or lactating women\n* Current use of immunosuppressive therapy\n* Unwillingness to participate or provide informed consent",{"count":171,"type":61},[501],"This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss and can significantly affect quality of life. Intralesional corticosteroids are commonly used as first-line therapy; however, response rates vary and treatment may be associated with discomfort and local adverse effects.\n\nSixty adult patients with patchy alopecia areata involving less than 50% of the scalp were randomly assigned to receive either topical calcipotriol or intralesional corticosteroid injections for 12 weeks. Participants were evaluated at four-week intervals. Treatment response was assessed using the Severity of Alopecia Tool (SALT) score and percentage improvement from baseline.\n\nThe primary objective is to compare reduction in SALT score between the two treatment groups. Secondary outcomes include overall treatment efficacy and safety. The findings aim to determine whether topical calcipotriol provides superior or comparable clinical benefit to intralesional corticosteroids in patients with alopecia areata.",[31],[31,533,534,535,508,536,537],"Topical Calcipotriol","Intralesional Corticosteroids","Randomized Controlled Trial","Vitamin D Analog","Patchy Alopecia","2026-03-02",{"date":540,"type":45},"2026-03-05",{"date":542,"type":61},"2026-04-01",{"date":544,"type":61},"2026-10-01",{"name":546,"class":283},"Hayat Abad Medical Complex, Peshawar",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":16,"minAge":358,"maxAge":90,"enrollmentInfo":554,"targetDuration":4,"studyType":62,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":567},"100505836","phase-2-dupilumab-in-the-treatment-of-pediatric-alopecia-areata-100505836","NCT05866562","Dupilumab in the Treatment of Pediatric Alopecia Areata","PEDAL","Inclusion Criteria:\n\n* Male or female participants who are at least 6 years old and under 18 years old, who can provide assent (if appropriate), and for whom signed informed consent can be provided by parent or legal guardian prior to participation in any study assessments or procedures\n\n  \\-- Participant is able to adhere to the study visit schedule and other protocol requirements.\n* Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:\n\n  * Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR\n  * Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural \\[animal\\] membrane \\[for example, polyurethane\\]);\n* Participant has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score.\n* Participant has a screening IgE ≥ 200 and\u002For personal and\u002For familial history of atopy (including asthma, atopic dermatitis, allergic rhinitis, food allergy, or eosinophilic esophagitis)\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n* Participant is pregnant or breastfeeding.\n* Participant's cause of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V).\n* Participant has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss.\n* Severe, uncontrolled asthma (having 2 or exacerbations in the last 12 months that require systemic steroids and\u002For hospitalization) or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic medications.\n* Participant has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics\n* Participant with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator.\n* Participant has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n* Known active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening for subjects determined by the investigators to be at high-risk for this disease.\n* Participant has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Participant has received a live attenuated vaccine ≤ 28 days prior to study randomization.\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n* History of adverse systemic or allergic reactions to any component of the study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, ritlecitinib, or investigational oral JAK Inhibitors) or ultraviolet (UV) phototherapy with\u002Fwithout Psoralen Ultraviolet A (PUVA) therapy, within 4 weeks prior to the Week 0\u002FBaseline visit\n* Participant has been previously treated with dupilumab\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus within 1 week before the Baseline visit.",{"count":431,"type":61},[173],"This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and\u002For have personal and\u002For familial history of atopy.\n\nStudy participation will be up to 124 weeks, consisting of: a screening period of up to 4 weeks; a 48-week placebo-controlled period; a 48-week open-label extension period; followed by a 24-week follow-up period.",[31],"2026-02-19",{"date":560,"type":45},"2026-02-20",{"date":562,"type":45},"2024-07-11",{"date":564,"type":61},"2029-04-30",{"name":566,"class":350},"Icahn School of Medicine at Mount Sinai",5,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":578,"conditions":579,"keywords":581,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":590},"100603434","a-real-world-study-to-globally-assess-disease-burden-in-adolescent-and-adult-participants-with-alopecia-areata-vitiligo-or-hidradenitis-suppurativa-100603434","NCT07136467","A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa","Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)","MEASUREAAVitHS","Inclusion Criteria:\n\n* Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)\n* Participants Ability to understand study questionnaires, with caregiver support as required for adolescents\n\nExclusion Criteria:\n\n* Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)\n* Unable or unwilling to comply with study requirements and PRO collection",{"count":577,"type":61},2795,"This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.",[580,31,33],"Non-Segmental Vitiligo (NSV)",[580,31,33],"2026-02-12",{"date":584,"type":45},"2026-02-13",{"date":586,"type":45},"2025-09-02",{"date":588,"type":61},"2027-08",{"name":47,"class":48},116,{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":62,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":4},"100624174","phase-4-tofacitinib-vs-methotrexate-for-severe-alopecia-areata-tofa-mtx-aa-100624174","NCT07406204","Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial","TOFA-MTX-AA","Inclusion Criteria:\n\nAdults aged 18-60 years.\n\nClinical diagnosis of severe alopecia areata, alopecia totalis, or alopecia universalis (as per protocol\u002Foperational definition), confirmed by a consultant dermatologist.\n\nEither sex.\n\nAble and willing to provide written informed consent.\n\nExclusion Criteria:\n\nCurrently receiving or recently used any systemic treatment intended for hair regrowth for alopecia areata (e.g., systemic corticosteroids, immunosuppressants, JAK inhibitors).\n\nPregnant women.\n\nHistory or clinical evidence of renal, hepatic, or pulmonary disease.\n\nAny condition that, in the investigator's judgment, makes participation unsafe or interferes with adherence to the study protocol.","60 Years",{"count":60,"type":61},[501],"This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair). Alopecia areata is an autoimmune condition that can cause significant hair loss and emotional distress.\n\nAdults aged 18 to 60 years with severe disease will be enrolled at the Department of Dermatology, MTI-Hayatabad Medical Complex, Peshawar, after ethical approval and written informed consent. Participants will be randomly assigned to receive either tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg\u002Fkg once weekly for 12 weeks.\n\nThe main outcome will be improvement in hair loss measured by the Severity of Alopecia Tool (SALT) score. Treatment will be considered effective if there is more than 50% improvement in SALT score from baseline at the end of 12 weeks. Safety will be monitored during follow-up visits. The findings may help guide treatment decisions for severe alopecia areata in our local population.",[31,604,384],"Alopecia Totalis (AT)",[606,607,608,609,509],"Tofacitinib","Methotrexate","Janus Kinase Inhibitor","Severe Alopecia Areata","2026-02-05",{"date":582,"type":45},{"date":613,"type":61},"2026-02-15",{"date":201,"type":61},{"name":546,"class":283},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":624,"targetDuration":4,"studyType":62,"phases":626,"briefSummary":627,"conditions":628,"keywords":631,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":105},"100612239","pallas-laser-for-skin-diseases-100612239","NCT07250997","PALLAS Laser for Skin Diseases","Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light","PALLAS-UV","Inclusion Criteria:\n\n1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,\n2. a skin condition that is expected to respond well to targeted UVB treatment,\n3. a signed consent form.\n\nExclusion Criteria:\n\n1. Patient under 18 years of age,\n2. pregnancy\n3. epilepsy,\n4. fever, infectious diseases,\n5. the patient is within one month or currently enrolled in another clinical trial.",{"count":625,"type":61},50,[333],"The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).\n\nThe secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases.\n\nThe patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial.\n\nThe treatment takes approximately 10 minutes per session, and can last up to 3 months per patient.\n\nPhotographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month.\n\nAt the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.",[629,630,31,23],"Vitiligo Vulgaris","Psoriasis",[632,633,634,635,68,636],"UVB laser treatment","PALLAS laser","vitiligo","psoriasis","atopic dermatitis",{"date":638,"type":45},"2026-02-06",{"date":640,"type":45},"2025-12-10",{"date":642,"type":61},"2026-12-31",{"name":644,"class":350},"Szeged University"]